G
GNi
Pharmaceutical and traditional Chinese medicine development company
About GNi
GNI Group Ltd. is a biopharmaceutical company engaged in the research, development, manufacture, and sale of pharmaceutical drugs and traditional Chinese medicines. Founded in 2001, the company is headquartered in Tokyo, Japan, with operations in China and the United States. GNI Group focuses on developing treatments for diseases that are prevalent in Asia, particularly cancer and inflammatory diseases.
The company operates through two main geographical segments: Japan and China. The Japan segment is responsible for licensing, preclinical studies, and clinical trials, while the China segment manages integrated biopharmaceutical operations, including validation, manufacturing, and sales. Dr. Ying Luo serves as the Director, President, and Chief Executive Officer of the company.
Source: Dealroom company dataAt a glance
- Founded
- 2001
- Headquarters
- San Jose, United States
Knowledge graph
More headlines
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A1 investor entered at this stage
HWVP
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about GNi on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See GNi on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.